• US Navy photographer tells the wild story of how she shot these stunning photos of F-35 stealth fighters

    2 monthes ago - By Business Insider

    When you look at the photo above, you see only a stunning image of three stealth fighters soaring in close formation.
    But, what you are actually looking at is the result of a billion-dollar dance directed by a talented US Navy camerawoman, who managed to pull off a perfect shot while puking her insides out.
    The awesome power of the US military is on display in thousands of photos taken by expert photographers like US Navy Chief Mass Communication Specialist Shannon Renfroe, who recently produced a collection of stunning photos of three F-35C Lightning II Joint Strike Fighters soaring over...
    Read more ...

     

  • Gilead's Liver-Drug Setback Jeopardizes $35 Billion Dream

    Gilead's Liver-Drug Setback Jeopardizes $35 Billion Dream

    2 monthes ago - By Washington Post

    A trial failure adds to doubts about the drugmaker's focus on NASH treatments as a golden goose.
    Read more ...

     

  • The competition's heating up over a $35 billion market to treat NASH, a 'silent disease' millions are living with. But some of the early results don't look promising

    The competition's heating up over a $35 billion market to treat NASH, a 'silent disease' millions are living with. But some of the early results don't look promising

    2 monthes ago - By Business Insider

    NASH, short for nonalcoholic steatohepatitis , is a type of liver disease in which liver fat builds up in people.
    It affects an estimated 16 million Americans, but many don't know it until it leads to more serious problems like liver failure and cirrhosis.
    Drugmakers are looking at different ways to treat the condition - both early and later as the disease progresses. Some are conducting research to better understand the genetics and other factors associated with NASH.
    On Monday, Gilead said that its first late-stage NASH trial for its drug selonsertib had failed. Analysts said the...
    Read more ...